Imatinib, a tyrosine kinase inhibitor used in cancer treatment, selectively inhibits the ABL kinase domain of the bcr-abl oncogenic protein present in patients with chronic myelogenous leukemia [131]. The gene discussed is PROS1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.